Sex: M
Vaccine: COVID19
Symptoms: Arthritis, C-reactive protein, Musculoskeletal discomfort, Rash
Clinical narrative: Patient started having joint problems; Patient has acquired arthritis; After the 2nd dose patient developed a rash; This spontaneous case was reported by a consumer and describes the occurrence of MUSCULOSKELETAL DISCOMFORT (Patient started having joint problems), ARTHRITIS (Patient has acquired arthritis) and RASH (After the 2nd dose patient developed a rash) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 21-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 18-Jun-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced MUSCULOSKELETAL DISCOMFORT (Patient started having joint problems), ARTHRITIS (Patient has acquired arthritis) and RASH (After the 2nd dose patient developed a rash). The patient was treated with PREDNISONE for Adverse event, at an unspecified dose and frequency. At the time of the report, MUSCULOSKELETAL DISCOMFORT (Patient started having joint problems) had not resolved, ARTHRITIS (Patient has acquired arthritis) outcome was unknown and RASH (After the 2nd dose patient developed a rash) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, C-reactive protein: elevated (High) C reactive protein was elevated.         Concomitant medications details were not reported by the reporter. Company comment: This spontaneous case concerns a male patient of unknown age with no reported medical history, who experienced the unexpected, non-serious AESI of Arthritis. The date of onset of the event was not specified in respect to the administration of second dose of mRNA-1273, hence latency could not be assessed. The first dose of mRNA-1273 was given 28 days prior to the administration of second dose. C-reactive protein was done on an unknown date with elevated results, patient is being treated with prednisone and other unnamed medication but his Arthritis still persisted. Details of general data, concomitant medications, medical history, clinical course and treatment were not provided. The benefit-risk relationship of mRNA-1273 is not affected by this report.; Sender's Comments: This spontaneous case concerns a male patient of unknown age with no reported medical history, who experienced the unexpected, non-serious AESI of Arthritis. The date of onset of the event was not specified in respect to the administration of second dose of mRNA-1273, hence latency could not be assessed. The first dose of mRNA-1273 was given 28 days prior to the administration of second dose. C-reactive protein was done on an unknown date with elevated results, patient is being treated with prednisone and other unnamed medication but his Arthritis still persisted. Details of general data, concomitant medications, medical history, clinical course and treatment were not provided. The benefit-risk relationship of mRNA-1273 is not affected by this report.